Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Trevi Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $595.8K in total
- Insiders trading
- 1
- Net value
- −$595.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Trevi Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Heffernan Michael Thomas | Director | 6,351 | Sep 17, 2026 | 2 |
| Vanlent Anne | Director | – | Jun 4, 2026 | 1 |
| Colangelo Dominick | Director | – | Jun 4, 2026 | 1 |
| Mathers Edward T | Director | 948,948Indirect | Jun 4, 2026 | 1 |
| Meeker David P | Director | 352,489 | Jun 4, 2026 | 1 |
| Good Jennifer L | President & CEO | 213,313 | Feb 20, 2026 | 1 |
| Sciascia Thomas | Chief Scientific Officer | 221,373 | Feb 20, 2026 | 1 |
| Cassella James V | Chief Development Officer | – | Feb 20, 2026 | 1 |
| Galletta Christopher | See Remarks | 26,095 | Feb 20, 2026 | 2 |
| Simon Farrell | Chief Commercial Officer | 76,900 | Feb 20, 2026 | 1 |
| Hastings David C | Chief Financial Officer | – | Jan 12, 2026 | 1 |
| Delfini Lisa | Chief Financial Officer | 64,660 | Jun 3, 2025 | 0 |
| Clark David J | Chief Medical Officer | – | Feb 16, 2024 | 0 |
| Bonderman David | Other: Former 10% Owner | 3,824,883Indirect | Jul 6, 2022 | 0 |
| Coulter James G | Other: Former 10% Owner | 3,824,883Indirect | Jul 6, 2022 | 0 |
| Winkelried Jon | Other: Former 10% Owner | 3,824,883Indirect | Jul 6, 2022 | 0 |
| TPG GP A, LLC | Other: Former 10% Owner | 3,824,883Indirect | Jul 6, 2022 | 0 |
| Forbes William P | Chief Development Officer | – | Jul 1, 2022 | 0 |
| New Enterprise Associates 16, L.P. | 10% Owner | 10,421,428 | Apr 13, 2022 | 0 |
| NEA Partners 16, L.P. | 10% Owner | 10,421,428 | Apr 13, 2022 | 0 |
| Nea 16 GP, LLC | 10% Owner | 10,421,428 | Apr 13, 2022 | 0 |
| Sandell Scott D | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
| Baskett Forest | 10% Owner | 10,421,428Indirect | Apr 13, 2022 | 0 |
| Walker Paul Edward | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
| Sonsini Peter W. | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
| Florence Anthony A. Jr. | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
| Behbahani Ali | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
| Makhzoumi Mohamad | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
| Chang Carmen | 10% Owner | 948,948Indirect | Apr 13, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 31, 2024 (view filing) | May 29 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −53.4K | $2.55 | −$136.1K | −19.9%214.4K after | |
| Aug 16, 2024 (view filing) | Aug 14-16 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −31.5K | $2.77 | −$87.3K | −12.5%220.3K after | 3 lots |
| Aug 21, 2024 (view filing) | Aug 19 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −16.5K | $2.96 | −$48.8K | −7.0%220.3K after | |
| Aug 29, 2024 (view filing) | Aug 27 | 2 days | Meeker David PDirector | SSale | −4.55K | $2.93 | −$13.3K | −1.3%352.5K after | |
| Sep 5, 2024 (view filing) | Sep 3-5 | 2 days | Good Jennifer LPresident & CEO | SSale | −55.1K | $3.09 | −$170.1K | −20.5%213.3K after | 3 lots |
| Sep 9, 2024 (view filing) | Sep 6-9 | 3 days | Good Jennifer LPresident & CEO | SSale | −6.06K | $3.03 | −$18.4K | −2.8%213.3K after | 2 lots |
| Mar 12, 2025 (view filing) | Mar 10 | 2 days | Simon FarrellChief Commercial Officer | SSale | −81.3K | $6.75 | −$549.1K | −51.4%76.9K after | 2 lots10b5-1 |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Good Jennifer LPresident & CEO | SSale | −5.26K | $6.58 | −$34.6K | −2.4%213.3K after | |
| Mar 26, 2025 (view filing) | Mar 25 | 1 day | Sciascia ThomasChief Scientific Officer | SSale | −2.63K | $6.60 | −$17.4K | −1.2%221.4K after | |
| Sep 17, 2026 (view filing)4:55 PM ET | Sep 15 | 2 days | Heffernan Michael ThomasDirector | SSale | −39.5K | $15.09 | −$595.8K | −86.1%6.35K after | 4 lots10b5-1 |